-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination ...
New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...
Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE ...
Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of inhibitor ...
Dr. Shune highlights that the growing availability of FDA-approved agents with distinct and complementary mechanisms has transformed cGVHD management. The ability to combine therapies targeting ...
Pelabresib plus Jakafi significantly reduced spleen volume and improved symptoms in myelofibrosis patients compared to Jakafi alone, with sustained benefits at 96 weeks. The combination therapy showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results